Published in Neurology on December 12, 2012
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci (2013) 1.82
Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain (2014) 1.70
Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. Neurology (2013) 1.53
APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol (2014) 1.07
What can biomarkers tell us about cognition in Parkinson's disease? Mov Disord (2014) 1.03
Predictors of mild cognitive impairment in early-stage Parkinson's disease. Dement Geriatr Cogn Dis Extra (2013) 0.95
Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov Disord (2015) 0.87
Salience network and parahippocampal dopamine dysfunction in memory-impaired Parkinson disease. Ann Neurol (2014) 0.86
Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease. Neurosci Biobehav Rev (2014) 0.86
CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Acta Neuropathol (2016) 0.86
Neuroimaging biomarkers for Parkinson disease: facts and fantasy. Ann Neurol (2014) 0.83
PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders. BMC Neurol (2014) 0.82
Recent imaging advances in neurology. J Neurol (2015) 0.81
Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease. Mov Disord (2015) 0.81
Cognition in movement disorders: where can we hope to be in ten years? Mov Disord (2014) 0.81
Cognitive reserve and β-amyloid pathology in Parkinson disease. Parkinsonism Relat Disord (2015) 0.80
PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies. Neurodegener Dis (2015) 0.80
Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease. J Parkinsons Dis (2015) 0.80
Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. Lancet Neurol (2016) 0.79
The Effect of Dopaminergic Medication on Beat-Based Auditory Timing in Parkinson's Disease. Front Neurol (2016) 0.79
Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. JAMA Neurol (2016) 0.79
Biomarkers in biological fluids for dementia with Lewy bodies. Alzheimers Res Ther (2014) 0.78
Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status. Parkinsonism Relat Disord (2014) 0.77
Imaging Amyloidopathy in Parkinson Disease and Parkinsonian Dementia Syndromes. Clin Transl Imaging (2015) 0.77
Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset. J Int Neuropsychol Soc (2015) 0.77
Cognitive decline in Parkinson disease. Nat Rev Neurol (2017) 0.77
Patterns of cortical thinning in nondemented Parkinson's disease patients. Mov Disord (2016) 0.76
Reply: Beyond the limits of detection: failure of PiB imaging to capture true Aβ burden. Mov Disord (2013) 0.76
Visual Hallucinations and Amyloid Deposition in Parkinson's Disease Dementia: A Case Report. Psychiatry Investig (2016) 0.75
Narrative Organization Deficit in Lewy Body Disorders Is Related to Alzheimer Pathology. Front Neurosci (2017) 0.75
Association of a BACE1 Gene Polymorphism with Parkinson's Disease in a Norwegian Population. Parkinsons Dis (2015) 0.75
Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia. Mov Disord Clin Pract (2016) 0.75
Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders. Front Hum Neurosci (2017) 0.75
Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease. J Mov Disord (2016) 0.75
Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias. Curr Neurol Neurosci Rep (2017) 0.75
Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis. J Parkinsons Dis (2017) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab (1996) 9.49
Imaging beta-amyloid burden in aging and dementia. Neurology (2007) 7.70
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain (2008) 5.89
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging (2010) 5.49
Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem (2003) 5.34
Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med (2005) 5.10
Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol (2003) 4.76
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol (2007) 4.11
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol (2007) 3.83
Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol (2011) 3.56
Imaging amyloid deposition in Lewy body diseases. Neurology (2008) 3.09
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain (2009) 3.03
A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol (1993) 3.00
Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord (2006) 2.96
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology (2010) 2.67
Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol (2011) 2.57
Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci (2011) 2.47
beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.40
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord (2011) 2.27
Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry (2008) 2.12
Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol (2011) 1.83
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Relationship of motor symptoms to intellectual deficits in Parkinson disease. Neurology (1982) 1.61
Cholinergic dysfunction in diseases with Lewy bodies. Neurology (2000) 1.58
Sharpen that needle. Arch Neurol (2010) 1.49
Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (2001) 1.31
Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol (1989) 1.27
Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. Mov Disord (2006) 1.12
Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment. Int J Clin Pract (2012) 1.04
Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease. Acta Neuropathol (1998) 0.99
Relation between clinical characteristics of Parkinson's disease and cognitive decline. J Clin Exp Neuropsychol (2003) 0.95
Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol (2007) 0.87
Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci (2009) 12.05
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron (2009) 7.02
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex (2008) 5.36
Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci (2009) 4.50
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol (2007) 3.83
Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol (2010) 3.64
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol (2011) 3.12
Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A (2007) 3.03
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol (2011) 2.81
Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med (2010) 2.77
Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am J Geriatr Psychiatry (2004) 2.70
Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation. Proc Natl Acad Sci U S A (2008) 2.65
Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol (2011) 2.57
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology (2013) 2.47
The A4 study: stopping AD before symptoms begin? Sci Transl Med (2014) 2.43
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol (2008) 2.31
Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun (2006) 2.27
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology (2012) 2.26
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med (2008) 2.10
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol (2003) 2.05
Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol (2006) 1.94
Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia (2012) 1.90
Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain (2011) 1.89
Brain amyloid and cognition in Lewy body diseases. Mov Disord (2012) 1.87
Stepwise connectivity of the modal cortex reveals the multimodal organization of the human brain. J Neurosci (2012) 1.82
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J Neurosci (2012) 1.76
Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc Natl Acad Sci U S A (2011) 1.76
Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B. Ann Neurol (2008) 1.74
Transferable, multiple antibiotic and mercury resistance in Atlantic Canadian isolates of Aeromonas salmonicida subsp. salmonicida is associated with carriage of an IncA/C plasmid similar to the Salmonella enterica plasmid pSN254. J Antimicrob Chemother (2008) 1.62
Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia (2011) 1.60
Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord (2008) 1.60
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.58
Effects of normal aging and Alzheimer's disease on emotional memory. Emotion (2002) 1.57
Executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer's disease. Alzheimers Dement (2011) 1.54
Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol (2010) 1.50
Sharpen that needle. Arch Neurol (2010) 1.49
Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging (2012) 1.49
A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery. Alzheimers Res Ther (2011) 1.48
Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging (2012) 1.43
Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults. J Neurosci (2011) 1.41
Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study. Mov Disord (2008) 1.41
Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain (2013) 1.40
Diagnosing dementia with Lewy bodies. Arch Neurol (2002) 1.40
Preservation of neuronal number despite age-related cortical brain atrophy in elderly subjects without Alzheimer disease. J Neuropathol Exp Neurol (2008) 1.33
Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. Am J Pathol (2011) 1.32
Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy. Neurology (2012) 1.29
Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study. Ann Neurol (2013) 1.27
Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol (2012) 1.25
Shorter telomeres may mark early risk of dementia: preliminary analysis of 62 participants from the nurses' health study. PLoS One (2008) 1.20
TAR-DNA binding protein 43 in Pick disease. J Neuropathol Exp Neurol (2008) 1.19
PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am J Hum Genet (2002) 1.19
Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease. JAMA Neurol (2013) 1.18
Age and amyloid-related alterations in default network habituation to stimulus repetition. Neurobiol Aging (2011) 1.16
CML24, regulated in expression by diverse stimuli, encodes a potential Ca2+ sensor that functions in responses to abscisic acid, daylength, and ion stress. Plant Physiol (2005) 1.14
Failure to modulate attentional control in advanced aging linked to white matter pathology. Cereb Cortex (2011) 1.12
Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol (2014) 1.12
MRI-guided SPECT perfusion measures and volumetric MRI in prodromal Alzheimer disease. Arch Neurol (2003) 1.08
Neuropsychiatric symptoms and global functional impairment along the Alzheimer's continuum. Dement Geriatr Cogn Disord (2012) 1.07
Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol (2008) 1.04
A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. J Labelled Comp Radiopharm (2013) 1.03
Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. J Neuropathol Exp Neurol (2013) 1.03
Working memory in mild Alzheimer's disease and early Parkinson's disease. Neuropsychology (2003) 1.02
Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study. Mov Disord (2011) 1.01
Instrumental activities of daily living impairment is associated with increased amyloid burden. Dement Geriatr Cogn Disord (2011) 1.01
Puzzling thoughts for H. M.: can new semantic information be anchored to old semantic memories? Neuropsychology (2004) 1.01
Selective reduction of soluble tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study. Acta Neuropathol (2003) 1.00
Amyloid deposition is linked to aberrant entorhinal activity among cognitively normal older adults. J Neurosci (2014) 1.00
Statistical adjustments for brain size in volumetric neuroimaging studies: some practical implications in methods. Psychiatry Res (2011) 1.00
In vivo characterization of the early states of the amyloid-beta network. Brain (2013) 0.99
A Luminex assay detects amyloid β oligomers in Alzheimer's disease cerebrospinal fluid. PLoS One (2013) 0.98
Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A (2012) 0.95
Relation between clinical characteristics of Parkinson's disease and cognitive decline. J Clin Exp Neuropsychol (2003) 0.95
Prevalence and effects of lobar microhemorrhages in early-stage dementia. Neurodegener Dis (2005) 0.94
Cognitive-behavioral therapy for patients with Parkinson's disease and comorbid major depressive disorder. Psychosomatics (2010) 0.93
Effects of Alzheimer disease on memory for verbal emotional information. Neuropsychologia (2004) 0.92
Test-retest reliability of memory task functional magnetic resonance imaging in Alzheimer disease clinical trials. Arch Neurol (2011) 0.91
Replication of association between ELAVL4 and Parkinson disease: the GenePD study. Hum Genet (2008) 0.91